| Document |
Document Title |
|
WO/2023/004080A2 |
The present disclosure in one aspect provides technologies for detection of pancreatic cancer, e.g., early detection of pancreatic cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or ...
|
|
WO/2023/287009A1 |
The present invention relates to ICG-loaded, folic acid-conjugated exosomes with improved tumor targeting ability, and a preparation method therefor. The exosomes according to the present invention are accumulated specifically on tumor c...
|
|
WO/2023/283732A1 |
There is described herein a bilayer nanovesicle comprising porphyrin-phospholipid conjugate and a chelator-fatty acid conjugate; wherein the chelator-fatty acid conjugate comprises an aminopolycarboxylic acid conjugated to a single chain...
|
|
WO/2023/287797A2 |
This disclosure provides a method of treating cancer or a blood disorder disease in a patient, the method comprising administering a therapeutically effective amount of a combination of compounds comprising (1) a hypomethylating agent (H...
|
|
WO/2023/287372A1 |
This invention relates to the development of enzyme carrier systems whose activity is triggered by near infrared light (NIR) to increase the activity of enzymes used in the healthcare or pharmaceutical industry, wherein it is characteriz...
|
|
WO/2023/284582A1 |
Disclosed is the use of a nano-carbon iron composite preparation in the preparation of a tumor thermotherapy drug matched with near-infrared light. During low-temperature thermotherapy, the composite preparation can reduce the dosage and...
|
|
WO/2023/283554A2 |
Provided herein are methods for reducing pigmentation in skin, hair, and/or eyes comprising administration of an effective amount of an nicotinamide nucleotide transhydrogenase (NNT) activator and/or Mitofusin 2 (MFN2) activator.
|
|
WO/2023/283386A2 |
Provided are therapeutic combinations comprising hallucinogenic agents and entactogenic agents. Also provided are compositions, such as pharmaceutical compositions, comprising such combinations and methods of using the same. In some embo...
|
|
WO/2023/283393A2 |
The invention provides methods for inducing satiety and treatment of metabolic disorders, diabetes, obesity, and obesity-related conditions. The methods include administration of a metabolic hormone via an intranasal, topical gastrointes...
|
|
WO/2023/276966A1 |
The present invention provides: a pharmaceutical composition with which cancer cells present at various locations in the body can be killed locally and with high efficiency; and a method therefor. According to the present invention, a fu...
|
|
WO/2023/277778A1 |
A yeast cell for use in the treatment and/or alleviation of inflammation and/or symptoms caused by inflammation, wherein the yeast cell has been treated with electromagnetic waves in the range of 1 GHz to 300 GHz, or said yeast cell has ...
|
|
WO/2023/278603A2 |
Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds in combination with immunotherapy and chemotherapy to treat di...
|
|
WO/2022/271619A1 |
Described herein are methods of treating cancer by administering to a subject a composition comprising ultrasmall silica nanoparticles to enhance one or more of the following immunotherapies: chimeric antigen receptor (CAR) T-cell therap...
|
|
WO/2022/271716A2 |
The invention features methods of treating a subject having a cytopenia associated with a myelodysplastic syndrome, a cytopenia associated with chronic myelomonocytic leukemia, or a cytopenia associated with myelofibrosis, such as anemia...
|
|
WO/2022/271877A2 |
Up-regulation of caspase has been found in COVID-19 patients, and also occurs in patients suffering from diabetes, hypertension, metabolic syndrome, and other conditions. Such up-regulation can be responsible for poor clinical outcomes i...
|
|
WO/2022/271944A2 |
Described herein are methods for treating a subject having or at risk of developing Gaucher disease, by administering one or more agents that increase expression and/or activity of glucocerebrosidase (GBA) and/or scavenger receptor class...
|
|
WO/2022/270143A1 |
The present invention provides a novel compound which can have the property of being specifically taken into cancer cells. Produced in the present invention is a novel 4-borono-phenylalanine derivative, a borono-phenylalanine derivative ...
|
|
WO/2022/271841A1 |
Provided is a method of treating a mental disorder in a patient. Also provided is a method of enhancing a therapeutic effect of a psychedelic drug in a patient with a mental disorder. Additionally provided is a method of reducing an adve...
|
|
WO/2022/271822A1 |
This invention relates generally to compositions and methods for increasing the efficacy of immunotherapies and vaccines. In particular, the present invention relates to compositions comprising one or more metabolites (derivatives, prodr...
|
|
WO/2022/266413A1 |
This document provides methods and materials for assessing and/or treating mammals (e.g., humans) having prostate cancer. In some cases, methods and materials for identifying a mammal (e.g., a human) as having a resistant prostate cancer...
|
|
WO/2022/266544A2 |
Provided are bacteriochlorin hydroporphyrin compounds that contain a single site for conjugation that includes a beta-pyrrole linker. Also provided are methods for producing the same and for using the same for diagnosis and/or therapy. T...
|
|
WO/2022/258960A1 |
A method (100) for synthesising multi-core magnetic metal oxide nanoparticles is disclosed. The method comprises providing a first precursor mixture (102) comprising a first metal-containing precursor, a first solvent, and a first nanopa...
|
|
WO/2022/257855A1 |
A h-BN/MoS 2 nanoprobe capable of achieving targeted photothermal and chemical synergistic therapy, a preparation method therefor, and an application. The preparation method comprises: mixing a h-BN nanosheet dispersion liquid and an FA-...
|
|
WO/2022/260136A1 |
Provided are: a surface-modified nanoparticle which can be produced easily and enables both of the selective delivery of a boron atom into a cancer cell and the retention of the boron atom; and a method for producing the surface-modified...
|
|
WO/2022/256734A1 |
Methods of non-contact lithotripsy are disclosed, wherein photonic nanoparticles are delivered in the vicinity of kidney stones, e.g. within a kidney. The nanoparticles then are irradiated with non-ionizing electromagnetic radiation to a...
|
|
WO/2022/252599A1 |
The use of a small molecule based on the structure of indole tricarbocyanine in the preparation of a tumor photothermal therapy drug. A large-conjugated water-soluble indole tricarbocyanine dye compound can be used as a photothermal ther...
|
|
WO/2022/256738A1 |
Triazenes and methods of producing diazonium species from said traizenes using ultraviolet (UV) light, which provide a fast, easy, stable, scalable, and selectively-triggerable means of modifying aromatic nucleophiles, including those on...
|
|
WO/2022/246557A1 |
There is provided adjunctive D-cycloserine (DCS) augmentation of transcranial magnetic stimulation (TMS) therapy for Major Depressive Disorder (MDD). There is also provided combination therapies and therapeutic methods that include inter...
|
|
WO/2022/251481A1 |
The invention relates, in part, to methods and compounds for radiosensitizing cells and increasing efficacy of treatments for cancers.
|
|
WO/2022/245907A1 |
This disclosure provides the single-component near-infrared light-controlled IsPadC-PCM-based optogenetic systems for prokaryotic and eukaryotic cells, consisting of an evolved photosensory core module of the Idiomarina sp. bacterial phy...
|
|
WO/2022/246204A2 |
Provided are oligomeric agents, oligomeric compounds, antisense agents, and pharmaceutical compositions for reducing the amount or activity of PTBP 1 RNA in a cell or animal, and in certain instances reducing the amount of PTBP 1 protein...
|
|
WO/2022/245900A2 |
Described are pharmaceutical compositions for treating an inflammatory condition, a neurologic condition and/or a vascular condition, the composition including i) a cannabinoid and Ii) a modulator compound that acts as one or more of an ...
|
|
WO/2022/245032A1 |
The present invention relates to a photoresponsive micelle complex for treatment of inflammatory diseases and, more specifically, to a photoresponsive micelle complex for prevention or treatment of inflammatory diseases or infectious dis...
|
|
WO/2022/246149A2 |
A system for communication with an electric vehicle charging station. The system includes an electric vehicle charging station for charging an electric vehicle, a network operations center providing wired or wireless communication to at ...
|
|
WO/2022/241295A2 |
According to some embodiments, genetically engineered cells capable of expressing a set of one or more olfactory signaling pathway genes that facilitate expression of an olfactory receptor are provided herein. The genetically engineered ...
|
|
WO/2022/241302A2 |
Disclosed are compositions and methods that may be useful in the treatment and/or prevention of hearing loss caused by genetic mutation of the STRC gene. The compositions and methods disclosed herein use Lentiviral vectors to facilitate ...
|
|
WO/2022/238603A1 |
The proposed invention relates to plasma-activated liquid media for use thereof in the treatment of diseases, whether viral and/or bacterial (including antibiotic-resistant bacteria), of the upper and lower respiratory tracts in humans a...
|
|
WO/2022/237864A1 |
It has been established that inhibition of macropinocytosis in cancer cells enhances the anti-cancer efficacy of photodynamic therapy (PDT). Methods for treating cancer in a subject in need thereof include administering to a subject with...
|
|
WO/2022/235077A1 |
The present invention relates to a novel siderophore compound, a complex in which same is conjugated to a metal nanoparticle, and a novel use of the complex.
|
|
WO/2022/233795A1 |
The present application relates to substituted dyes containing bis-boron fused heterocycles and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
|
|
WO/2022/234266A1 |
A method of distributing microparticles is provided, the method comprising: providing a plurality of microparticles at an insertion site in a medium; applying ultrasound to the insertion site that generates gas bubbles by cavitation at c...
|
|
WO/2022/235791A2 |
Described herein is a combination therapy for the treatment of a cancer in a subject. In one aspect, the therapy comprises selinexor and one or more second anti-cancer agents.
|
|
WO/2022/235040A1 |
The present invention relates to a complex for bioimaging, diagnosis, and treatment of cancer cells. The complex of the present invention comprises fluorescent nanoparticles and a manganese salt conjugated to the surface of the fluoresce...
|
|
WO/2022/232586A1 |
The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Examples of the diseases inclu...
|
|
WO/2022/232614A2 |
Methods and compositions are provided for treating individuals who have an oncogene-negative cancer. In some cases, such individuals have an oncogene-negative tumor(s). In some cases, they have an oncogene-negative lung cancer. In some c...
|
|
WO/2022/223626A1 |
The present invention relates to ultrasound mediated enhancement of immunotherapeutic medicinal agents and regimens, and particularly forimmunotherapeutic treatment of cancers and autoimmune diseases. More particularly, the invention pro...
|
|
WO/2022/224202A1 |
The present disclosure includes a boron containing complex that includes a boron compound including boron-10 (10B); and a carrier compound including a right-handed coiled coil-nanotube (RHCC-NT) portion, the RHCC-NT portion having at lea...
|
|
WO/2022/221464A2 |
A method for preventing and treating micrometastasis in a patient with cancer, especially breast cancer or glioblastoma tumors, by silencing TRAF3IP2 before during or in connection with treatment as described herein.
|
|
WO/2022/221559A2 |
Described herein are compositions and methods for assessing and modulating ceramide and sphingomyelin in neurological disorders.
|
|
WO/2022/221208A1 |
Various methods, systems, and devices for treating tissue ablation are disclosed. Several embodiments disclosed herein pertain to methods of treating tumors, systems used for irradiating tissue and tumors with electromagnetic radiation, ...
|
